Hepatoblastoma Study
RNA sequencing for study samples. Patients with metastatic, treatment-refractory, and relapsed hepatoblastoma (HB) have survival rates of less than 50% due to limited treatment options. To develop new therapeutic strategies for these patients, our lab has developed a preclinical testing pipeline.